ArticleEndocrine2021

Inhibition of the RANKL with denosumab has no effect on circulating markers of atherosclerosis in women with postmenopausal osteoporosis: a pilot study.

Cristiana Cipriani et al.PubMed ↗Publisher ↗

No numbers read from the abstract.